You are about to leave the Clinical Value website now.

Cancel

Diagnostic challenges in primary hepatocellular carcinoma: case reports and review of the literature

Quick Summary

Hepatocellular carcinoma is the fifth most common malignancy and the third leading mortality cause worldwide. It typically develops secondarily to liver cirrhosis, due to hepatitis B or C infection, alcohol abuse, metabolic disease, and so forth. According to the American Association for the Study of Liver Diseases (AASLD) guidelines, which constitute diagnostic standards, the diagnosis of primary hepatocellular carcinoma (HCC) should be based on contrast-enhanced imaging. Lesion hyperenhancement should be observed throughout the arterial phase, followed by the washout during the venous phase. The diagnosis can also be based on the histopathological evaluation of liver biopsy specimen. Although the standards are clear, we often see patients with advanced HCC in clinical practice, who cannot be offered any effective treatment. Patients with chronic liver disease, presenting with inconclusive and changeable test results, constitute a separate problem. In such cases the diagnostic process is typically long-term and delayed. In this paper, they present three case reports where the diagnosis could not be made promptly and the patients died as a result of a delayed diagnostic process.

Authors: Monika Pazgan-Simon, Sylwia Serafinska, Justyna Janocha-Litwin, Krzysztof Simon, Jolanta Zuwala-Jagiello

You May Also Like

17 March 2023

Utility of Combining PIVKA-II and AFP in the Surveillance and Monitoring of Hepatocellular Carcinoma in the Asia-Pacific Region

A panel of 17 experts from Asia-Pacific, gathered to discuss and reach a consensus on the clinical usefulness and value of PIVKA-II for the surveillance and treatment monitoring of HCC,…

Read More
17 March 2023

A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma

This review highlights promising candidate biomarkers and biomarker panels that have completed phase II evaluation for the early detection of HCC. Parikh ND, Mehta AS, Singal AG, Block T, Marrero…

Read More
13 February 2024

The Pursuit for Better Patient Outcomes – Innovating HCC Management at Siriraj Hospital

Read More

SHARE

Be the first to receive updates, event opportunities, and thought leadership insights.